
Daniel M. Halperin, MD, discusses the FDA approval of lutetium Lu 177 dotatate for pediatric patients with SSTR-positive GEP-NETs.

Your AI-Trained Oncology Knowledge Connection!


Daniel M. Halperin, MD, discusses the FDA approval of lutetium Lu 177 dotatate for pediatric patients with SSTR-positive GEP-NETs.

Daniel M. Halperin, MD, discusses the efficacy and safety results of the phase 1/2a Protocol PEN-221-001 trial in advanced gastrointestinal mid-gut neuroendocrine tumors.